Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

Donanemab In May of 2023, two months prior to the full approval of lecanemab, another promising treatment for the disease, Eli Lilly’s donanemab, emerged from Phase III trials.

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busting drug ...

A strategy that analyzes the structural properties of RNA could help identify regions that are promising targets for antiviral drugs.

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Every three seconds, someone in the world develops dementia. Alzheimer’s disease is the most common form of dementia, accounting for between 60 per cent and 70 per cent of all cases. Although ...